Tandem Diabetes (NASDAQ: TNDM) reported Q3 EPS of ($0.31), $0.01 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $249.25 million versus the consensus estimate of $237.11 million.

GUIDANCE:

Tandem Diabetes sees FY2025 revenue of ~$1 billion, versus the consensus of $1.002 billion.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.